Drugs that contain Umeclidinium Bromide; Vilanterol Trifenatate
1. Anoro Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7361787 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 25 days ago) | |
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 25 days ago) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 10 days from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 1 month from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 10 days from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 3 months from now) | |
|
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 7 months from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(4 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Mai...
Dosage: POWDER;INHALATION
ANORO ELLIPTA family patents
